Completed PHASE2 INTERVENTIONAL 2-arm NCT01106703

The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE Levels

The Effects of PG102 on Allergy-related Risk Factors: A Randomized, Double Blind, Placebo Controlled Study

Sponsor: Ministry of Health & Welfare, Korea

Conditions Asymptomatic Subjects With Atopy and Elevated Serum IgE

Interventions PG102, a water soluble extract from Actinidia arguta placebo

Updated 6 times since 2017 Last updated: Jul 23, 2010 Started: Dec 31, 2006 Primary completion: Mar 31, 2008 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Asymptomatic Subjects With Atopy and Elevated Serum IgE and is currently completed. Ministry of Health & Welfare, Korea leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ministry of Health & Welfare, Korea
Seoul National University Hospital

Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seongnam-si, South Korea
• Seoul, South Korea